Remicade/Remicade Biosimilars REFERRAL FORM

FAX REFERRAL TO: +1(844) 277-0049 **PHONE:** +1(844) 650-5802



1	PATIENT'S INF	ORMATION (Com	plete or include demographic sheet)				
	Patient Name:		DOB:	G	Sender: MALE	FFMΔLF	
	Address:		DOB: (WALL INALL		
		y Phone: Email:					
	Emergency Contact:			Phone:			
2	INSURANCE (Pleas	NSURANCE (Please attach If Available a copy of the Patients' insurance card(s) Front/ Back)					
	Primary Insurance: Group: Policy No: Group:						
	Primary RX Insurance:						
3							
	Diagnosis (ICD-10) and Patient Cl	linical Information:					
	Drug Allergies:		NKDA H	lt: i	n/cm Wt:	lbs/Kg	
	Diagnosis (ICD-10):	Description:					
	Pre-Clinical Information:						
	TB Test Date:	B Test Date: Positive (+) Negative (-) Hepatitis-B Test Date: F				Reactive (-)	
	Labs: Please fax copy of the following labs dated within 1 year of the patients referral request:						
	□CMP □CBCw/ diff □Hepatitis (B) □QuantiFERON (QFT) / TB/ T-Spot						
4	PRESCRIPTION	INFORMATION	O N				
•							
	ACCESS: IV PORT RX INFORMATION: Our pharmacist will identify clinically appropriate brand (Unless product is specifically specified at the time of referral) and						
	nfusion rate per FDA guidelines. Clinically appropriate substitutions may be allowed based on availability or payor requirements. Dose(s) will be						
	rounded to the nearest vial size. Official orders will be outlined with "May Infuse" +/- 3 days if scheduling needs arises, with insurance payor approval".						
	PRODUCTS: ☐ Avsola ☐ Inflectra ☐ Infliximab ☐ Remicade ☐ Renflexis						
	LOADING DOSE: mg/Kg or mg (TOTAL) Infuse on weeks and then every weeks for 1 Year, unless specified						
	MAINTENANCE DOSE: mg/Kg or mg (TOTAL) Infuse IV every weeks for 1 Year, Unless Specified.						
	PRE/POST ORDERS:						
	MEDICATION SoluMedrol® (IV)		DIRECTION		QUANTITY	REFILLS	
	Diphenhydramine: PO IV		a IV push diluted inin Prior to Infusion. May repeat every		Quantity: Q.S Quantity: Q.S	Refills: PRN Refills: PRN	
			min Prior to Infusion. May repeat ev		Quantity: Q.S	Refills: PRN	
	Hydration: 0.9% NaCL LR		solution before		Quantity: Q.S	Refills: PRN	
	Emla® cream Apply topically 30 to 60 minutes prior to access.				Quantity: Q.S	Refills: PRN	
	ANAPHYLAXIS PROTOCOL:						
	MEDICATION	Administer IM for sovere an	aphylactic reaction. May repeat	t in E-15 minutes	QUANTITY	REFILLS	
	X EPINEPHRINE (vial or autoinjector)		0.15 mg (Wt 15-30 kg) 0.1 mg (V		Quantity: (x1) Vial or (x2) Pen(s)	Refills: PRN	
	M		w IV push for severe <u>an</u> aphylac		(AZ) F eli(S)	Neiills. FRIN	
	X DIPHENHYDRAMINE (50mg/mL)	50 mg (Wt > 30 kg)	25 mg (Wt 15-30 kg) 12.5mg (Wt 7.5-15kg)	Quantity: (x1) Vial(s)	Refills: PRN	
	X SODIUM CHLORIDE 0.9% (IV)	Infuse 500 mL IV as o	directed for severe anaphylactic	reaction.	Quantity: 500 mL	Refills: PRN	
	NURSING/ LABS/ INFUSION SUPPLIES: NURSING: Nursing visits with each infusion to establish venous access, administer medication, assess and monitor patient, provide education, and complete lab draws INFUSION SUPPLIES: Infusion supplies and infusion pump PRN for the administration and disposal of medication. FLUSHING PROTOCOL: Sodium chloride 0.9%, up to 10 mL before/after medication, and/or PRN to maintain patency.						
Heparin: 10 Units/mL 100 Units/mL, as final flush and/or PRN to maintain patency LABS: [Dx code: Z79.899]; Labs to be drawn by RN prior to infusion every Week Month(s), as followed: CMP CBC w/ diff Sed Rate LFT Hepatitis-B Other:							
5 PRESCRIBER INFORMATION							
	Prescriber Name:						
	Address: City/ State/ Zip:						
	Phone: Fax: Contact Person: Contact Person: The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record.						
		uthorize IV Solutions RX and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future refills of the same escription for the patient listed above. I understand that I can revoke the designation at any time by providing written notice to IV Solutions RX. DNFIDENTIALITY NOTICE: The information contained in this transmission may contain confidential information, including patient information protected by federal and state privacy laws. It is tended only for the use of the person(s) named above. If not the intended recipient, you are hereby notified that any review, dissemination, distribution, or duplication of this communication.					
	CONFIDENTIALITY NOTICE: The information						
	intended only for the use of the person(s) ha					communication	

Physicians signature